'Drawing on our decades of experience in inflammation, we're looking forward to advancing new treatment areas like Sjögren's syndrome and uncontrolled gout.'Īt ACR, new results will be presented from the Phase 2 study of dazodalibep, an investigational therapy for Sjögren's. Reese, M.D., executive vice president of Research and Development at Amgen. 'The data at ACR will illustrate our continued growth in rheumatology as we advance unique treatment approaches across a broader range of diseases,' said David M. More than 20 abstracts will be presented during the American College of Rheumatology (ACR) Convergence 2023, taking place Nov. 1, 2023 /PRNewswire/ - Amgen (NASDAQ:AMGN) today announced the presentation of new scientific and clinical research across its expanded rheumatology pipeline and portfolio, following the recent acquisition of Horizon Therapeutics.
Clinical Trial Diversity and RepresentationĬlinical Trial Transparency, Data Sharing and Disclosure PracticesĪdverse Event and Product Complaint ReportingĮnvironmental, Social & Governance Report 2022Įnvironment, Social and Governance StrategyĬommunity Investment and Amgen Foundationīreadth of Research Reflects Amgen's Commitment to Rheumatologyĭata Include Sjögren's Syndrome, Uncontrolled Gout, Severe Active ANCA-Associated Vasculitis and Psoriatic Arthritis
